Ken Griffin’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $153K | Sell |
19,800
-100,900
| -84% | -$736K | ﹤0.01% | 11663 |
|
|
2025
Q4 | $740K | Buy |
120,700
+98,500
| +444% | +$1.06M | ﹤0.01% | 8083 |
|
|
2025
Q3 | $409K | Sell |
22,200
-45,400
| -67% | -$729K | ﹤0.01% | 9617 |
|
|
2025
Q2 | $879K | Buy |
67,600
+46,000
| +213% | +$544K | ﹤0.01% | 7390 |
|
|
2025
Q1 | $229K | Sell |
21,600
-4,900
| -18% | -$77.8K | ﹤0.01% | 10184 |
|
|
2024
Q4 | $450K | Sell |
26,500
-9,300
| -26% | -$175K | ﹤0.01% | 8801 |
|
|
2024
Q3 | $831K | Sell |
35,800
-7,400
| -17% | -$158K | ﹤0.01% | 7233 |
|
|
2024
Q2 | $1.05M | Buy |
43,200
+22,000
| +104% | +$667K | ﹤0.01% | 6480 |
|
|
2024
Q1 | $716K | Sell |
21,200
-15,300
| -42% | -$542K | ﹤0.01% | 7623 |
|
|
2023
Q4 | $1.15M | Sell |
36,500
-4,300
| -11% | -$102K | ﹤0.01% | 6406 |
|
|
2023
Q3 | $1.04M | Buy |
40,800
+1,400
| +4% | +$43.1K | ﹤0.01% | 6480 |
|
|
2023
Q2 | $1.13M | Buy |
39,400
+2,100
| +6% | +$57.2K | ﹤0.01% | 6208 |
|
|
2023
Q1 | $894K | Sell |
37,300
-96,400
| -72% | -$1.73M | ﹤0.01% | 7028 |
|
|
2022
Q4 | $2.27M | Buy |
133,700
+30,600
| +30% | +$534K | ﹤0.01% | 5241 |
|
|
2022
Q3 | $1.53M | Buy |
103,100
+13,600
| +15% | +$228K | ﹤0.01% | 6119 |
|
|
2022
Q2 | $1.41M | Sell |
89,500
-1,700
| -2% | -$33.4K | ﹤0.01% | 6255 |
|
|
2022
Q1 | $2.46M | Sell |
91,200
-7,000
| -7% | -$179K | ﹤0.01% | 5639 |
|
|
2021
Q4 | $3.63M | Buy |
98,200
+32,700
| +50% | +$1.33M | ﹤0.01% | 4949 |
|
|
2021
Q3 | $3.13M | Buy |
65,500
+39,700
| +154% | +$1.78M | ﹤0.01% | 5260 |
|
|
2021
Q2 | $873K | Sell |
25,800
-52,700
| -67% | -$1.78M | ﹤0.01% | 8702 |
|
|
2021
Q1 | $3.24M | Sell |
78,500
-85,100
| -52% | -$5.07M | ﹤0.01% | 5252 |
|
|
2020
Q4 | $7.1M | Buy |
163,600
+120,800
| +282% | +$8.18M | ﹤0.01% | 3101 |
|
|
2020
Q3 | $1.84M | Sell |
42,800
-7,600
| -15% | -$377K | ﹤0.01% | 4874 |
|
|
2020
Q2 | $2.36M | Buy |
50,400
+34,400
| +215% | +$1.19M | ﹤0.01% | 4291 |
|
|
2020
Q1 | $217K | Buy |
+16,000
| New | +$205K | ﹤0.01% | 7880 |
|
|
2017
Q1 | – | Sell |
-1,871
| Closed | -$28K | – | 7400 |
|
|
2016
Q4 | $28K | Buy |
1,871
+142
| +8% | +$2.12K | ﹤0.01% | 7005 |
|
|
2016
Q3 | $30K | Sell |
1,729
-614
| -26% | -$19.8K | ﹤0.01% | 6961 |
|
|
2016
Q2 | $74K | Buy |
2,343
+714
| +44% | +$22.5K | ﹤0.01% | 6307 |
|
|
2016
Q1 | $43K | Buy |
1,629
+900
| +123% | +$30.5K | ﹤0.01% | 6283 |
|
|
2015
Q4 | $32K | Buy |
+729
| New | +$32.8K | ﹤0.01% | 7619 |
|
|
2015
Q3 | – | Sell |
-4,057
| Closed | -$186K | – | 8852 |
|
|
2015
Q2 | $186K | Buy |
4,057
+3,286
| +426% | +$151K | ﹤0.01% | 6419 |
|
|
2015
Q1 | $30K | Sell |
771
-300
| -28% | -$13.2K | ﹤0.01% | 7695 |
|
|
2014
Q4 | $28K | Sell |
1,071
-5,843
| -85% | -$186K | ﹤0.01% | 7582 |
|
|
2014
Q3 | $747K | Buy |
+6,914
| New | +$901K | ﹤0.01% | 4086 |
|
Other funds holding ARCT
AIM
NAMA
VCM
VPM
Ken Griffin's ARCT Position: Q1 2026 in Review
Ken Griffin opened a new position in Arcturus Therapeutics (ARCT) in Q1 2026: 34,782 shares worth $269K. The stake represents ﹤0.01% of the portfolio and ranks #10725 among its holdings. This is a return to the name: Ken Griffin previously reported a position in ARCT as recently as Q3 2025.
Ken Griffin first reported a position in ARCT in Q4 2014 and has held it in 30 quarters since. The position peaked at $32.6M in Q2 2020. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.
- Ken Griffin held 34,782 shares of Arcturus Therapeutics worth $269K as of Q1 2026.
- Arcturus Therapeutics was a new Ken Griffin position in Q1 2026.
- Arcturus Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #10725 holding.
- Ken Griffin first reported a position in Arcturus Therapeutics in Q4 2014 and has held it in 30 quarters since.
- Ken Griffin's Arcturus Therapeutics position peaked at $32.6M in Q2 2020.
- 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.